Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin

International Journal of Cancer

Volumn 77, Issue 5, 1998, Pages 720-727

  Zagozdzon, Radoslław ^a,b   GolŁab, Jakub ^a   StoklŁosa, Tomasz ^a   Giermasz, Adam ^a   Nowicka, Dorota ^b   Feleszko, Wojciech ^a   Lasek, Witold ^a   Jakóbisiak, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DEPLETION; DRUG EFFICACY; FEMALE; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA; LEUKEMIA CELL; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; X IRRADIATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; LEUKEMIA L1210; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; PACLITAXEL; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TIME FACTORS; WHOLE-BODY IRRADIATION;

EID: 2642620202     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980831)77:5<720::AID-IJC10>3.0.CO;2-5     Document Type: Article

References (34)

1. AWWAD, M. and NORTH, R.J., Sub-lethal, whole-body ionizing irradiation can be tumor-promotive or tumor-destructive, depending in the state of development of underlying anti-tumor immunity. Cancer Immunol. Immunother., 26, 55-60 (1988).
2. BAXEVANIS, C.N., GRITZAPIS, A.D., DEDOUSSIS, G.V., TSITSILONIS, O.E. and PAPAMICHAIL, M., Induction of lymphokine-activated killer activity in mice by prothymosis α. Cancer Immunol. Immunother., 38, 281-286 (1994).
3. BELARDELLI, F., GRESSER, I., MAURY, C. and MAUNOURY, M.T., Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. II. Role of host mechanisms. Int. J. Cancer, 30, 821-825 (1982).
4. BOGDAN, C. and DING, A., Taxol, a microtubule-stabilizing anti-neoplastic agent, induces expression of tumor necrosis factor α and interleukin-1 in macrophages. J. Leukocyte Biol., 52, 119-121 (1992).
5. BRUNDA, M.J., LUISTRO, L., HENDRZAK, J.A., FOUNTOULAKIS, M., GAROTTA, G. and GATELY, M.K., Role of interferon-γ in mediating the anti-tumor efficacy of interleukin-12. J. Immunother., 17, 71-77 (1995).
6. BRUNDA, M.J., LUISTRO, L., RUMENNIK, L., WRIGHT, R.B., DVOROZNIAK, M., AGLIONE, A., WIGGINTON, J.M., WILTROUT, R.H., HENDRZAK, J.A. and PALLERONI, A.V., Anti-tumor activity of interleukin 12 in pre-clinical models. Cancer Chemother. Pharmacol., 38, S16-S21 (1996).
7. BRUNDA, M.J., LUISTRO, L., WARRIER, R.R., WRIGHT, R.B., HUBBARD, B.R., MURPHY, M., WOLF, S.F. and GATELY, M.K., Anti-tumor and anti-metastatic activity of interleukin 12 against murine tumors. J. exp. Med., 178, 1223-1230 (1993).
8. CHAN, S.H., PERUSSIA, B., GUPTA, J.W., KOBAYASHI, M., POSPÍŠIL, M., YOUNG, H., WOLF, S.F., YOUNG, D., CLARK, S.C. and TRINCHIERI, G., Induction of interferon-γ production by natural-killer-cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J. exp. Med., 173, 869-879 (1991).
9. COHEN, S.A., EHRKE, M.J., RYOYAMA, K. and MINICH, E., Augmentation of the phagocytic activity of murine spleen-cell populations induced by adriamycin. Immunopharmacol., 5, 75-84 (1982).
10. COHEN, S.A., SALAZAR, D. and WICHER, J., Adriamycin-induced activation of NK activity may initially involve LAP production. Cancer Immunol. Immunother., 15, 188-193 (1983).
11. D'ANDREA, A. and 12 OTHERS, Production of natural-killer-cell stimulatory factor (interleukin 12) by peripheral-blood mononuclear cells. J. exp. Med., 176, 1387-1398 (1992).
12. DOUZONO, M., SUZU, S., YAMADA, M., YANAI, N., KAWASHIMA, T., HATAKE, K. and MOTOYOSHI, K., Augmentation of cancer chemotherapy by preinjection of human macrophage-colony-stimulating factor in L1210 leukemic-cell-inoculated mice. Jap. J. Cancer Res., 86, 315-321 (1995).
13. EHRKE, M.J., MACCUBIN, D., RYOYAMA, K., COHEN, S.A. and MINIH, E., Correlation between adriamycin-induced augmentation of interleukin-2 production and of cell-mediated cytotoxicity in mice. Cancer Res., 46, 54-60 (1986).
14. EPPSTEIN, D.A., VAN DER PAS, M.A., MARSH, Y.V., BRUNO, N.A. and KURAHARA, C.G., Enhanced anti-tumor efficacy of adriamycin in combination with interferon-γ: effect on macrophages. J. Interferon Res., 8, 263-273 (1988).
15. FEFER, A., MCCOY, J.L. and GLYNN, J.P., Studies on growth and regression of a transplantable Moloney sarcoma. Cancer Res., 27, 2207-2211 (1967).
16. FLEISCHMANN, C.M., STANTON. G.J. and FLEISCHMANN, W.R., Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J. Interferon Cytokine Res., 16, 805-812 (1996).
17. GATELY, M.K., DESAI, B.B., WOLITZKY, A.G., QUINN, P.M., DWYER, C.M., PODLASKI, F.J., FAMILLETTI, P.C., SINIGAGLIA, F., CHIZZONITE, R., GUBLER, U. and STERN, A.S., Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol., 147, 874-882 (1991).
18. GOLŁAB, J. and 12 OTHERS, Granulocyte-macrophage colony-stimulating factor potentiates antitumor activity of interleukin-12 in melanoma model in mice. Tumor Biol., 19, 77-87 (1998a).
19. GOLŁAB, J., STOKLŁOSA, T., ZAGOŻDŻON, R., KACA, A., GIERMASZ, A., POJDA, Z., MACHAJ, E., DABROWSKA, A., FELESZKO, W., LASEK, W., IWAN-OSIECKA, A. and JAKOBISIAK, M., G-CSF prevents the suppression of bone-marrow hematopoiesis induced by IL-12 and augments its anti-tumor activity in a melanoma model in mice. Ann. Oncol., 9, 63-69 (1998b).
20. KOBAYASHI, M., FITZ, L., RYAN, M., HEWICK, R.M., CLARK, S.C., CHAN, S., LOUDON, R., SHERMAN, F., PERUSSIA, B. and TRINCHIERI, G., Identification and purification of natural-killer stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. exp. Med., 170, 827-845 (1989).
21. LASEK, W., FELESZKO, W., GOLŁAB, J., STOKLŁOSA, T., MARCZAK, M., DABROWSKA, D., MALEJCZYK, M. and JAKÓBISIAK, M., Anti-tumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor α in mice. Cancer Immunol. Immunother., 45, 100-108 (1997).
22. LASEK, W., GIERMASZ, A., KUC, K., WAŃKOWICZ, A., GOLŁAB, J., ZAGOŻDŻON, R., STOKLŁOSA, T. and JAKÓBISIAK, M., Potentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice: correlation between results of in vitro and in vivo studies. Int. J. Cancer, 66, 374-379 (1996).
23. LIN, T.Z. and PONZIO, N.M., Syngeneic B-lymphoma cells provide a unique stimulus to natural-killer(NK) cells in genetically low-NK SJL/J mice. J. Leukocyte Biol. 49, 48-57 (1991).
24. MACCUBBIN, D.L., WING, K.R., MACE, K.F., HO, R.L.X., EHRKE, J. and MINICH, E., Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res., 52, 3572-3576 (1992).
25. MACE, K., MAYHEW, E., MINICH, E. and EHRKE, M.J., Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res., 48, 130-136 (1988).
26. MANETTI, R., PARRONCHI, P., GIUDIZI, M.G., PICCINI, M.P., MAGGI, E. and TRINCHIERI, G., Natural-killer stimulatory factor [interleukin 12 (IL-12)] induces T-helper-type-1(Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. exp. Med., 177, 1199-1204 (1993).
27. + T lymphocytes, and NK cells. J. Immunol., 149, 3495-3502 (1992).
28. ROBERTSON, M.J., SOIFFER, R.J., WOLF, S.F., MANLEY, T.J., DONAHUE, C., YOUNG, D., HERRMANN, S.H. and RITZ, J., Response of human natural-killer(NK) cells to NK-cell stimulatory factor (NKSF): cytolitic activity and proliferation of NK cells are differentially regulated by NKSF. J. exp. Med., 175, 779-788 (1992).
29. SODHI, A., SINGH, R.K. and PAI, K., Activation of murine macrophages by tumor necrosis factor, interleukin-1, interferon-γ and cisplatin. Immunol. Lett., 26, 45-50 (1990).
30. TRICHER, B.A., ARA, G., BUXTON, D., LEONARD, J. and SCHAUB, R.G., Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. Clin. Cancer Res., 3, 1661-1667 (1997).
31. TZAI, T.S., LIN, J.S. and CHOW, N.H., Modulation of anti-tumor immunity of tumor-bearing mice with low-dose cyclophosphamide. J. surg. Res., 65, 139-144 (1996).
32. VERBIK, D.J., STINSON, W.W., BRUNDA, M.J., KESSINGER, A. and JOSHI, S.S., In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin. exp. Metastas., 14, 219-229 (1996).
33. YAMAUE, H., TANIMURA, H., NOGUCHI, K., IWAHASHI, M., TSUNODA, T., TANI, M., TAMAI, M., HOTTA, T., MIZOBATA, S. and ARII, K., Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells. J. Clin. Lab. Immunol., 35, 165-170 (1991).
34. ZAGOŻDŻON, R., STOKLŁOSA, T., GOLŁAB, J., GIERMASZ, A., LASEK, W. and JAKÓBISIAK, M., Augmented anti-tumor effects of combination therapy with interleukin-12, cisplatin and tumor necrosis factor-α in a murine melanoma model. Anticancer Res., 17, 4493-4498 (1997).